Volker Herrmann, Flagship CEO-Partner and CEO of Sonata Therapeutics, explains why the Sonata platform is focused first on indications rather than targets as it develops novel Network MedicinesTM through an engineered and programmable design process. More from Flagship @ JPM2024 here.
Related Companies
- Sonata Therapeutics Founded: 2022
